Avian Flu Drug Zanamivir Clears SFDA For Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
A bird flu drug developed by Shanghai Institute of Materia Medica, Nanjing Xian Sheng Dong Yuan Pharmaceutical and Nanjing Yifang Center for Pharmaceutical R&D have passed preclinical appraisal of China's State FDA Center for Drug Evaluation. The zanamivir capsule and its raw material drug received SFDA's approval Nov. 7 to enter clinical trials. Zanamivir, a neuraminidase inhibitor for the treatment of influenza caused by type A virus, is the second most effective avian flu drug after oseltamivir. (Click here for more - Chinese Language)